198 related articles for article (PubMed ID: 12759881)
21. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
22. Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes.
Toledo FG; Menshikova EV; Ritov VB; Azuma K; Radikova Z; DeLany J; Kelley DE
Diabetes; 2007 Aug; 56(8):2142-7. PubMed ID: 17536063
[TBL] [Abstract][Full Text] [Related]
23. Non-oxidative glucose disposal is reduced in type 2 diabetes, but can be restored by aerobic exercise.
Yokoyama H; Mori K; Emoto M; Araki T; Teramura M; Mochizuki K; Tashiro T; Motozuka K; Inoue Y; Nishizawa Y
Diabetes Obes Metab; 2008 May; 10(5):400-7. PubMed ID: 18410564
[TBL] [Abstract][Full Text] [Related]
24. Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model.
Koopmans SJ; Mroz Z; Dekker R; Corbijn H; Ackermans M; Sauerwein H
Metabolism; 2006 Jul; 55(7):960-71. PubMed ID: 16784971
[TBL] [Abstract][Full Text] [Related]
25. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
26. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
Phillips SA; Ciaraldi TP; Kong AP; Bandukwala R; Aroda V; Carter L; Baxi S; Mudaliar SR; Henry RR
Diabetes; 2003 Mar; 52(3):667-74. PubMed ID: 12606507
[TBL] [Abstract][Full Text] [Related]
27. The role of troglitazone in treating the insulin resistance syndrome.
Granberry MC; Schneider EF; Fonseca VA
Pharmacotherapy; 1998; 18(5):973-87. PubMed ID: 9758309
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of troglitazone action in type 2 diabetes.
Petersen KF; Krssak M; Inzucchi S; Cline GW; Dufour S; Shulman GI
Diabetes; 2000 May; 49(5):827-31. PubMed ID: 10905493
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Basu R; Shah P; Basu A; Norby B; Dicke B; Chandramouli V; Cohen O; Landau BR; Rizza RA
Diabetes; 2008 Jan; 57(1):24-31. PubMed ID: 17914032
[TBL] [Abstract][Full Text] [Related]
30. Retinoid X receptor expression in skeletal muscle of nondiabetic, obese and type 2 diabetic individuals.
Codner E; Loviscach M; Ciaraldi TP; Rehman N; Carter L; Mudaliar S; Henry RR
Metabolism; 2001 Jul; 50(7):830-4. PubMed ID: 11436190
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
[TBL] [Abstract][Full Text] [Related]
32. Comparison of lipid profiles and lipoprotein a levels in patients with type 2 diabetes mellitus during oral hypoglycemic or insulin therapy.
Habib SS; Aslam M; Naveed AK; Razi MS
Saudi Med J; 2006 Feb; 27(2):174-80. PubMed ID: 16501671
[TBL] [Abstract][Full Text] [Related]
33. Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia.
Smith AC; Mullen KL; Junkin KA; Nickerson J; Chabowski A; Bonen A; Dyck DJ
Am J Physiol Endocrinol Metab; 2007 Jul; 293(1):E172-81. PubMed ID: 17374701
[TBL] [Abstract][Full Text] [Related]
34. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects.
Park KS; Ciaraldi TP; Abrams-Carter L; Mudaliar S; Nikoulina SE; Henry RR
J Clin Endocrinol Metab; 1998 May; 83(5):1636-43. PubMed ID: 9589670
[TBL] [Abstract][Full Text] [Related]
35. Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats.
Iida KT; Kawakami Y; Suzuki M; Shimano H; Toyoshima H; Sone H; Shimada K; Iwama Y; Watanabe Y; Mokuno H; Kamata K; Yamada N
Am J Physiol Endocrinol Metab; 2003 Jun; 284(6):E1125-30. PubMed ID: 12569086
[TBL] [Abstract][Full Text] [Related]
36. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
37. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Frias JP; Yu JG; Kruszynska YT; Olefsky JM
Diabetes Care; 2000 Jan; 23(1):64-9. PubMed ID: 10857970
[TBL] [Abstract][Full Text] [Related]
38. Troglitazone directly inhibits CO(2) production from glucose and palmitate in isolated rat skeletal muscle.
Fürnsinn C; Brunmair B; Neschen S; Roden M; Waldhäusl W
J Pharmacol Exp Ther; 2000 May; 293(2):487-93. PubMed ID: 10773019
[TBL] [Abstract][Full Text] [Related]
39. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
[TBL] [Abstract][Full Text] [Related]
40. Metabolic effects of Troglitazone in patients with diet-controlled type 2 diabetes.
Robinson AC; Jeffs JA; Gray RG; Bannister PA; Mather H; Gallagher JJ; Robinson S; Nattrass M; Venkatesan S; Halliday D; Johnston DG
Eur J Clin Invest; 2004 Jan; 34(1):29-36. PubMed ID: 14984435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
